hcv

[anonymous]

Humira will take us into 2022. Imbruvica will take over any Humira loss. Ricky has great things planned for all of us. Don't listen to the angry mole Loots song boy, His meds wear off and he gets angry. Looks like his federal assistance will be halted when trump takes over.

 

[anonymous]

Humira will take us into 2022. Imbruvica will take over any Humira loss. Ricky has great things planned for all of us. Don't listen to the angry mole Loots song boy, His meds wear off and he gets angry. Looks like his federal assistance will be halted when trump takes over.

"Imbruvica will take over any Humira loss"... great insight, but numbers don't support your argument

Imbruvica 1q16 sales @ $381M with an annual run rate of only $1.5B >>> not even close to $12B target

*** paid $21B for Imbruvica, WOW that's a long break even rate

 

[anonymous]

This is hilliarious 2 funny. Viekira Going up up up 79% already

 

[anonymous]

One of the S&P 500’s big LOSERS for Wednesday May 11 was Gilead Sciences Inc. (GILD). The company’s stock fell 2.65% to $83.90 on volume of 8.21 million shares.
The stock opened the day at 86.39 and traded between a low of $83.81 and a high of $86.40. The stock finished the day down $2.28 per share. Gilead Sciences Inc. has an average daily volume of 12.37 million and a total float of 1.33 billion shares. The 50-day SMA for Gilead Sciences Inc. is $92.73 and its 200-day SMA is $99.08. The high for the stock over the last 52 weeks is $123.37 and the low is $81.89.
THE MOLE IS CRYING ....2 FUNNI
and
Hilliarious

 

[anonymous]

The HCV sales force will be retained because we have a 2nd generation product coming. However, we must not let the 3 stooges near the drug!!

 

[anonymous]

If Y'all don't want Hassie Lootsie or Gonzo involved, Who should handle it, Gosebruch and his team ?

 

[anonymous]

This is hilliarious 2 funny. Viekira Going up up up 79% already

Unfortunately if you keep repeating false information,,, it won't change the downward trend

 

[anonymous]

The HCV sales force will be retained because we have a 2nd generation product coming. However, we must not let the 3 stooges near the drug!!

Too late and will offer no competitive advantage....sound familiar?

 

[anonymous]

Why does Haas make so much money, because of increase in our Hep C market ?

 

[anonymous]

Too late and will offer no competitive advantage....sound familiar?

yep

 

[anonymous]

Why does Haas make so much money, because of increase in our Hep C market ?

Yep Yep, because he increased sales by 79% and knows Hep C like the back of his hand. He just received 3800 qualified options for Q1 @ $62 each. How come we don't receive options ?
We are pushing product but don't get respect. At least I'm not at Gilead I heard it's a bloodbath in HV because of Discounted vouchers and VA budget running out by Q4. 45 reps were PIPd and let go. You think Jeff will reduce head count ? I don't think so because we are breaking stride

 

[anonymous]

The HCV sales force will be retained because we have a 2nd generation product coming. However, we must not let the 3 stooges near the drug!!

Oh, you mean 3D? 3 pills ones a day.. Yeah, just how is that better than the competition?

This franchise is boxed end of year.

 

[anonymous]

You been saying that for last two years. How come we are still here ? Why do you love Gilead so much ? I smell a RAT !

 

[anonymous]

You been saying that for last two years. How come we are still here ? Why do you love Gilead so much ? I smell a RAT !

What you smell are the savory aromas passed out of Lootsie Louie Louie

 

[anonymous]

Yep Yep, because he increased sales by 79% and knows Hep C like the back of his hand. He just received 3800 qualified options for Q1 @ $62 each. How come we don't receive options ?
We are pushing product but don't get respect. At least I'm not at Gilead I heard it's a bloodbath in HV because of Discounted vouchers and VA budget running out by Q4. 45 reps were PIPd and let go. You think Jeff will reduce head count ? I don't think so because we are breaking stride

You sound like a dillusional Metabolics rep. The only stride you break is your downhill stride that shows nothing but decreases in sales. Every one of HCV's planned follow ons is behind the competition from every perspective.

As earlier poster said:

Metabolics is dead and HCV is circling the drain.

HCV would of been ditched already if not for the huge black eye it gives AbbVie to so obviously missed the mark so miserably.

Be prepared for HUGE territories and lots of driving and lonely hotel nights away from home as they continue to attrit this travesty.

Signed,
Your friendly Onc reps

 

[anonymous]

"You think Jeff will reduce head count ?"

He didn't have to, cause 50% of the HCV sales team bolted & was never replaced

 

[anonymous]

Give it a BREAK!

 

[anonymous]

"You think Jeff will reduce head count ?"

He didn't have to, cause 50% of the HCV sales team bolted & was never replaced

-> so Ricky will only have to spent half of what he did last year on chocolate, since there are 50% less reps

 

[anonymous]

Did we PIP that many ? I know only a handful left on their own in HCV. The rest were put on plan and let go after they didn't meet sales criteria.

 

[anonymous]

who would ever leave hv, pulling in 90k base 12k plan and working 20 hours a week !